Other‐cause mortality in incidental prostate cancer
The Prostate · 2024
DOI: 10.1002/pros.24689 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Francesco Di Bello und 19 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, SEER Program, Incidental Findings. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Background
In incidental prostate cancer (IPCa), elevated other‐cause mortality (OCM) may obviate the need for active treatment. We tested OCM rates in IPCa according to treatment type and cancer grade and we hypothesized that OCM is significantly higher in not‐actively‐treated patients.
Methods
Within the Surveillance, Epidemiology, and End Results database (2004−2015), IPCa patients were identified. Smoothed cumulative incidence plots as well as multivariable competing risks regression models were fitted to address OCM after adjustment for cancer‐specific mortality (CSM).
Results
Of 5121 IPCa patients, 3655 (71%) were not‐actively‐treated while 1466 (29%) were actively‐treated. Incidental PCa not‐actively‐treated patients were older and exhibited higher proportion of Gleason sum (GS) 6 and clinical T1a stage. In smoothed cumulative incidence plots, 5‐year OCM was 20% for not‐actively‐treated versus 8% for actively‐treated patients. Conversely, 5‐year CSM was 5% for not‐actively‐treated versus 4% for actively‐treated patients. No active treatment was associated with 1.4‐fold higher OCM, even after adjustment for age, cancer characteristics, and CSM. According to GS, OCM reached 16%, 27%, and 35% in GS 6, 7, and 8−10 not‐actively‐treated IPCa patients, respectively and exceeded CSM recorded for the same three groups (2%, 6%, and 28%, respectively).
Conclusion
Our results quantified OCM rates, confirming that in not‐actively‐treated IPCa patients OCM is indeed significantly higher than in their actively‐treated counterparts (HR: 1.4). These observations validate the use of no active treatment in IPCa patients, in whom OCM greatly surpasses CSM (20% vs. 5%).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
- Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
- Department of Urology, IRCCS Policlinico San Donato, Milan, Italy.
- Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
- Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Department of Urology, Vita-Salute San Raffaele University, Milan, Italy.
ORCID-Profile: Francesco Di Bello, Claudia Collà Ruvolo, Simone Morra
Zitieren
APA
Di Bello, F., Baudo, A., de Angelis, M., Jannello, L. M. I., Siech, C., Tian, Z., Goyal, J. A., Collà Ruvolo, C., Califano, G., La Rocca, R., Morra, S., Acquati, P., Saad, F., Shariat, S. F., Carmignani, L., de Cobelli, O., Briganti, A., Chun, F. K. H., Longo, N., & Karakiewicz, P. I. (2024). Other‐cause mortality in incidental prostate cancer. The Prostate. https://doi.org/10.1002/pros.24689
Vancouver
Di Bello F, Baudo A, de Angelis M, Jannello LMI, Siech C, Tian Z, et al. Other‐cause mortality in incidental prostate cancer. The Prostate. 2024. doi:10.1002/pros.24689
BibTeX
@article{DiBello2024,
author = {Di Bello, Francesco and Baudo, Andrea and de Angelis, Mario and Jannello, Letizia Maria Ippolita and Siech, Carolin and Tian, Zhe and Goyal, Jordan A and Collà Ruvolo, Claudia and Califano, Gianluigi and La Rocca, Roberto and Morra, Simone and Acquati, Pietro and Saad, Fred and Shariat, Shahrokh F and Carmignani, Luca and de Cobelli, Ottavio and Briganti, Alberto and Chun, Felix K H and Longo, Nicola and Karakiewicz, Pierre I},
title = {Other‐cause mortality in incidental prostate cancer},
journal = {The Prostate},
year = {2024},
doi = {10.1002/pros.24689}
}
EUVIMED